Parathyroid hormone treatment for glucocorticoid-induced osteoporosis

Nancy E Lane, Q. Rehman

Research output: Contribution to journalArticle

Abstract

Parathyroid hormone (PTH) was first used in the treatment of osteoporosis in 1929 when Fuller Albright demonstrated an increase in skeletal calcium in rats by injecting parathyroid extracts (1). This was later confirmed by Hans Selye in 1932 (2). The amino acid sequencing of PTH was performed in the early 1970s (3). Subsequently, small clinical studies were initiated to determine if PTH had therapeutic potential to augment bone mass in osteoporotic patients (4). Since then, a lot has been learned about the role of the amino terminal fragments of PTH in the treatment and prevention of osteoporosis in animals and humans. This article reviews the available evidence for the use of PTH fragments in osteoporosis, particularly glucocorticold-induced osteoporosis (GIOP).

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume18
Issue number5 SUPPL. 21
StatePublished - 2000
Externally publishedYes

Fingerprint

Parathyroid Hormone
Glucocorticoids
Osteoporosis
Protein Sequence Analysis
Therapeutics
Calcium
Bone and Bones

Keywords

  • Glucocorticoid-induced osteoporosis
  • Human parathyroid hormone (hPTH) (1-34)

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Parathyroid hormone treatment for glucocorticoid-induced osteoporosis. / Lane, Nancy E; Rehman, Q.

In: Clinical and Experimental Rheumatology, Vol. 18, No. 5 SUPPL. 21, 2000.

Research output: Contribution to journalArticle

@article{8390f70a055a4a9f94b62a90a3451018,
title = "Parathyroid hormone treatment for glucocorticoid-induced osteoporosis",
abstract = "Parathyroid hormone (PTH) was first used in the treatment of osteoporosis in 1929 when Fuller Albright demonstrated an increase in skeletal calcium in rats by injecting parathyroid extracts (1). This was later confirmed by Hans Selye in 1932 (2). The amino acid sequencing of PTH was performed in the early 1970s (3). Subsequently, small clinical studies were initiated to determine if PTH had therapeutic potential to augment bone mass in osteoporotic patients (4). Since then, a lot has been learned about the role of the amino terminal fragments of PTH in the treatment and prevention of osteoporosis in animals and humans. This article reviews the available evidence for the use of PTH fragments in osteoporosis, particularly glucocorticold-induced osteoporosis (GIOP).",
keywords = "Glucocorticoid-induced osteoporosis, Human parathyroid hormone (hPTH) (1-34)",
author = "Lane, {Nancy E} and Q. Rehman",
year = "2000",
language = "English (US)",
volume = "18",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5 SUPPL. 21",

}

TY - JOUR

T1 - Parathyroid hormone treatment for glucocorticoid-induced osteoporosis

AU - Lane, Nancy E

AU - Rehman, Q.

PY - 2000

Y1 - 2000

N2 - Parathyroid hormone (PTH) was first used in the treatment of osteoporosis in 1929 when Fuller Albright demonstrated an increase in skeletal calcium in rats by injecting parathyroid extracts (1). This was later confirmed by Hans Selye in 1932 (2). The amino acid sequencing of PTH was performed in the early 1970s (3). Subsequently, small clinical studies were initiated to determine if PTH had therapeutic potential to augment bone mass in osteoporotic patients (4). Since then, a lot has been learned about the role of the amino terminal fragments of PTH in the treatment and prevention of osteoporosis in animals and humans. This article reviews the available evidence for the use of PTH fragments in osteoporosis, particularly glucocorticold-induced osteoporosis (GIOP).

AB - Parathyroid hormone (PTH) was first used in the treatment of osteoporosis in 1929 when Fuller Albright demonstrated an increase in skeletal calcium in rats by injecting parathyroid extracts (1). This was later confirmed by Hans Selye in 1932 (2). The amino acid sequencing of PTH was performed in the early 1970s (3). Subsequently, small clinical studies were initiated to determine if PTH had therapeutic potential to augment bone mass in osteoporotic patients (4). Since then, a lot has been learned about the role of the amino terminal fragments of PTH in the treatment and prevention of osteoporosis in animals and humans. This article reviews the available evidence for the use of PTH fragments in osteoporosis, particularly glucocorticold-induced osteoporosis (GIOP).

KW - Glucocorticoid-induced osteoporosis

KW - Human parathyroid hormone (hPTH) (1-34)

UR - http://www.scopus.com/inward/record.url?scp=0033769061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033769061&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033769061

VL - 18

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5 SUPPL. 21

ER -